EKF moves to make inroads in molecular Dx market

03/4/2013 | Clinica (subscription required)

EKF Diagnostics has agreed to acquire 360 Genomics, which specializes in mutation detection technology, for $2.4 million worth of company stock and as much as $12.1 million in milestone cash payments. The deal will allow EKF to expand its point-of-care testing portfolio as well as make inroads in the molecular diagnostics arena.

View Full Article in:

Clinica (subscription required)

Published in Briefs:

SmartBrief Job Listings for Health Care